ICH E6(R3) Structure Overview
ICH E6(R3), with Step 4 adoption on 06 January 2025, represents the most significant revision to GCP guidelines since 1996. The Step 2 draft was released for public consultation in May 2023. This reference provides a quick navigation guide to the restructured document.
Document Architecture
| Component | Purpose | Applicability |
|---|
| Overarching Principles | Foundational GCP principles | All clinical trials |
| Annex 1 | Detailed requirements for interventional IMP trials | Interventional medicinal product trials |
| Annex 2 | Additional considerations for non-traditional approaches | Decentralized trials, digital technologies, pragmatic trials |
Overarching Principles (Sections 1-3)
Section 1: Introduction and Purpose
Key Points:
- Establishes scope applicable to interventional clinical trials of investigational medicinal products
- Emphasizes human participant protection and data reliability
- Introduces proportionate, risk-based approaches
Section 2: Principles of ICH E6(R3)
The guideline articulates 11 overarching principles that provide a flexible framework for clinical trial conduct throughout the trial life cycle. These principles are interdependent and should be considered in their totality to assure ethical trial conduct and reliable results.
| Principle | Title | Focus |
|---|
| Principle 1 | Ethical Conduct and Participant Protection | Clinical trials should be conducted in accordance with ethical principles from the Declaration of Helsinki, consistent with GCP and applicable regulatory requirements. Rights, safety, and well-being of participants are paramount. |
| Principle 2 | Informed Consent | Informed consent is integral to ethical trial conduct. Participation should be voluntary, based on a consent process ensuring participants are well-informed. |
| Principle 3 | IRB/IEC Review | Clinical trials should be subject to independent review by an IRB/IEC with documented prior approval before trial initiation. |
| Principle 4 | Scientific Soundness | Clinical trials should be scientifically sound for their intended purpose, based on adequate and current scientific knowledge and approaches. |
| Principle 5 | Qualified Individuals | Clinical trials should be designed and conducted by individuals qualified by education, training, and experience. |
| Principle 6 | Quality by Design | Quality should be built into the scientific and operational design and conduct of clinical trials, with focus on factors critical to quality. |
| Principle 7 | Proportionate Risk-Based Approach | Trial processes, measures, and approaches should be proportionate to risks to participants and importance of data collected, avoiding unnecessary burden. |
| Principle 8 | Protocol Requirements | Clinical trials should be described in a clear, concise, scientifically sound, and operationally feasible protocol. |
| Principle 9 | Reliable Results | Clinical trials should generate reliable results with appropriate data systems, record management, and transparency through registration and results posting. |
| Principle 10 | Roles and Responsibilities | Roles and responsibilities in clinical trials should be clear and documented appropriately, with sponsors and investigators retaining overall responsibility even when activities are delegated. |
| Principle 11 | Investigational Product Management | Investigational products should be manufactured in accordance with applicable GMP standards and managed according to product specifications and trial protocol. |
Key E6(R3) Enhancements:
- Principles 6 and 7 introduce the risk-proportionate, quality-by-design approach central to E6(R3)
- Principle 9 emphasizes data reliability, computerized systems validation, and trial transparency
- Principle 10 addresses the complex ecosystem of sponsors, investigators, and service providers with clear accountability
Section 3: Quality Management
Critical Concepts:
- Critical to Quality (CtQ) Factors: Elements essential to participant protection and data reliability
- Risk-Based Quality Management: Prospective identification, assessment, and control of risks
- Proportionality: Activities scaled to risk level of the trial
Annex 1: Interventional Clinical Trials of Investigational Medicinal Products
A1.1 Institutional Review Board/Independent Ethics Committee
| Topic | Key Content |
|---|
| Responsibilities | Protocol review, continuing review, safety monitoring |
| Composition | Qualified membership requirements |
| Documentation | Records of meetings, decisions, member qualifications |
A1.2 Investigator
| Topic | Key Content |
|---|
| Qualifications | Education, training, experience requirements |
| Resources | Adequate facilities, equipment, staff |
| Medical care | Participant medical decisions |
| Informed consent | Process and documentation |
| Protocol compliance | Adherence to approved protocol |
| Safety reporting | Adverse event documentation and reporting |
| Data recording | Accurate, complete, timely data entry |
A1.3 Sponsor
| Topic | Key Content |
|---|
| Quality management | System implementation, CtQ identification |
| Investigator selection | Qualification assessment |
| Protocol development | Scientific and ethical design |
| Safety evaluation | Ongoing benefit-risk assessment |
| Data management | Systems for reliable data collection |
| Monitoring | Risk-based monitoring strategy |
| Regulatory compliance | Submissions and communications |
A1.4 Clinical Trial Protocol
Required Protocol Elements:
| Category | Elements |
|---|
| General information | Title, sponsor ID, investigators, sites |
| Background | Scientific rationale, preclinical/clinical data |
| Objectives/Endpoints | Primary and secondary endpoints |
| Design | Study type, randomization, blinding |
| Population | Inclusion/exclusion criteria |
| Treatments | Dosing, administration, compliance |
| Assessments | Schedule of events, procedures |
| Safety | AE definitions, reporting requirements |
| Statistics | Sample size, analysis methods |
| Quality management | CtQ factors, risk mitigation |
A1.5 Investigator's Brochure
| Section | Content |
|---|
| Physical/Chemical | Drug substance properties |
| Nonclinical | Pharmacology, toxicology data |
| Clinical | PK, PD, safety, efficacy data |
| Guidance | Dosing, monitoring recommendations |
A1.6 Essential Documents
Three Categories:
- Before clinical phase begins: Regulatory approvals, protocol, IB, consent forms
- During clinical conduct: CRFs, SAE reports, monitoring reports
- After trial completion: Final reports, IP disposition, study report
Annex 2: Additional Considerations
A2.1 Decentralized Clinical Trials (DCTs)
Considerations for Remote Conduct:
| Aspect | Guidance |
|---|
| Participant safety | Remote monitoring capabilities |
| Consent process | Electronic consent considerations |
| Data collection | Direct data capture methods |
| IP distribution | Direct-to-participant shipping |
| Oversight | Remote monitoring approaches |
A2.2 Digital Health Technologies (DHTs)
| Topic | Key Points |
|---|
| Validation | Fit-for-purpose validation requirements |
| Data integrity | Electronic systems controls |
| Participant training | Device usage instruction |
| Technical support | Help desk availability |
A2.3 Non-Traditional Trial Designs
Addressed Designs:
- Adaptive trials
- Master protocols (basket, umbrella, platform)
- Pragmatic trials
- Real-world evidence integration
Key Changes from E6(R2)
| Area | E6(R2) | E6(R3) |
|---|
| Structure | Single document | Principles + 2 Annexes |
| Principles | 13 principles (Section 2) | 11 overarching principles (Section II) |
| Quality management | Introduced RBQM | Central organizing principle |
| Technology | Limited guidance | Extensive DHT coverage |
| Flexibility | Prescriptive | Outcome-focused |
| Trial types | Traditional focus | Non-traditional addressed |
| Monitoring | Risk-based introduced | Centralized monitoring emphasized |
Quick Reference: Section Finder
Looking for guidance on...
| Topic | Primary Location |
|---|
| Informed consent | A1.2.5 (Investigator section) |
| Protocol amendments | A1.4.5 |
| SAE reporting | A1.2.7 (Investigator), A1.3.8 (Sponsor) |
| Monitoring | A1.3.10 |
| Essential documents | A1.6 |
| Decentralized trials | A2.1 |
| Electronic systems | A2.2 |
| Source documentation | A1.2.8 |
Implementation Timeline
| Region | Expected Implementation |
|---|
| ICH regions | Phased implementation through 2025-2026 |
| FDA | Draft guidance aligned with E6(R3) |
| EMA | Incorporated into EU CTR framework |
Verify current status with relevant regulatory authority as timelines evolve.
